Frontier Bio

Frontier Bio is a private, pre-clinical stage biotech company pioneering advanced tissue engineering solutions. Its core strategy is dual-pronged: commercializing human-based in-vitro tissue models and services for research and drug development, while advancing its flagship program of a living, patient-specific vascular graft for surgical applications. The company is positioned at the convergence of two significant market shifts: the regulatory push to reduce animal testing and the urgent, unmet clinical need for durable vascular grafts and, ultimately, transplantable organs. Leadership comprises serial entrepreneurs and PhD-level scientists with deep expertise in bioprinting, vascular engineering, and biomaterials.

Platform for biofabricating living, three-dimensional human tissues, featuring bioresorbable scaffolds for bedside seeding with autologous stem cells to create implantable vascular grafts, and engineered human microtissues for in-vitro research.

Competes in the vascular graft space against large medical device companies (e.g., Gore, BD) selling synthetic grafts and other tissue engineering startups (e.g., Humacyte) developing acellular or cell-based vessels. In the in-vitro model space, competes with organ-on-a-chip companies (e.g., Emulate, Mimetas) and other tissue service providers.